FDA Approves Infliximab Biosimilar for Subcutaneous Use Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease. https://t.co/YnbisOzf0L https://t.co/9AyxEBpasb